Comparing Pembrolizumab vs Rituximab
| Pembrolizumab | Rituximab |
|
|---|
| Pembrolizumab | Rituximab |
|
|---|---|---|
|
Prescription only
Prescribed for Bladder Cancer, Breast Cancer, Cervical Cancer, Biliary Tract Tumor, Colorectal Cancer, Endometrial Cancer, Esophageal Carcinoma, Gastric Cancer, Head and Neck Cancer, Hepatocellular... View more |
Prescription only
Rituximab (brand name Rituxan) is a CD20 monoclonal antibody that causes B-cells to self-destruct or disintegrate and may be used to treat Non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia... View more |
|
| More about Pembrolizumab | More about Rituximab | |
| Ratings & Reviews | ||
|
Pembrolizumab has an average rating of 5.2 out of 10 from a total of 281 ratings on Drugs.com. 43% of reviewers reported a positive effect, while 44% reported a negative effect. |
Rituximab has an average rating of 7.7 out of 10 from a total of 170 ratings on Drugs.com. 69% of reviewers reported a positive effect, while 14% reported a negative effect. |
|
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||
View all Pembrolizumab side effects |
View all Rituximab side effects |
|
| Drug Class | ||
| Generic Availability | ||
|
N/A |
N/A |
|
| Pricing and Coupons * Prices are without insurance | ||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
|
| Dosage Forms | ||
|
N/A |
N/A |
|
| Brand Names | ||
| Keytruda | Riabni, Rituxan, Ruxience, Truxima | |
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||
|
624 hours |
59.8 hours |
|
| CSA Schedule 1 View glossary of CSA terms | ||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
|
| Pregnancy Category | ||
|
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
|
| Drug Interactions | ||
|
A total of 589 drugs are known to interact with Pembrolizumab:
|
A total of 192 drugs are known to interact with Rituximab:
|
|
| Alcohol/Food/Lifestyle Interactions | ||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
| Disease Interactions | ||
| First Approval Date | ||
|
N/A |
N/A |
|
| WADA Class View classifications | ||
|
N/A |
N/A |
|
| More Information | ||
| Patient Resources | ||
| Professional Resources | ||
| Related Treatment Guide | ||
|
|
|
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Verzenio
Verzenio is used to treat early and advanced-stage hormone receptor-positive, HER2-negative breast ...
Trodelvy
Trodelvy (sacituzumab govitecan) is a targeted therapy used to treat breast cancer (triple-negative ...
Epkinly
Epkinly is used for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) ...
Enhertu
Enhertu is a treatment for breast cancer, stomach cancer, and non-small cell lung cancer with HER2 ...
Opdivo Qvantig
Opdivo Qvantig is used to treat adults with melanoma, non-small cell lung cancer, renal cell ...
Rybrevant
Rybrevant is used to treat certain types of non-small cell lung cancer (NSCLC) in adults. It is ...
Kisqali
Kisqali (ribociclib) is used to treat a certain type of advanced metastatic breast cancer. Includes ...
Opdivo
Opdivo is used to treat many cancers, such as melanoma, non-small cell lung cancer, malignant ...
Keytruda
Keytruda is used to treat multiple types of cancer such as melanoma, non-small cell lung cancer ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.